Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients

N I Paton, P J Newton, D R Sharpstone, H M Ross, J Cotton, Alexander Graham Calder, Eric Milne, M Elia, S Shah, P Engrand, D C Macallan, B G Gazzard, G E Griffin

    Research output: Contribution to journalArticle

    33 Citations (Scopus)

    Abstract

    OBJECTIVES: A 12-week course of recombinant human growth hormone is an effective but expensive therapy for established HIV-related wasting. Wasting in HIV disease is often episodic, coinciding with bouts of acute opportunistic infection. We hypothesized that a short course of growth hormone, targeted at the time of opportunistic infection, might improve protein metabolism thereby reducing lean tissue loss. METHODS: HIV-infected men with acute opportunistic infections, who received standard antimicrobial treatment for their infection as well as intensive nutritional counselling and oral energy supplements, were randomized to receive growth hormone or placebo for 14 days. Principal assessments were protein metabolism (measured by 13C-leucine infusion), body composition (measured by DEXA) and safety. RESULTS: There were no significant changes in outcome parameters in the placebo group (n = 11). In the growth hormone group (n = 9), protein catabolic rate decreased by 60% in the fasted state (P = 0.02 versus placebo), lean body mass increased by 2.2 kg (P = 0.03 versus baseline) and fat mass decreased by 0.7 kg (P = 0.002 versus baseline). There was no increase in adverse or serious adverse events in the growth hormone as compared with the placebo group. CONCLUSIONS: A two-week course of growth hormone at the time of acute opportunistic infection in HIV-infected patients improves protein metabolism and body composition during therapy and appears to be safe. This may represent a rational and economical approach to the use of growth hormone therapy.
    Original languageEnglish
    Pages (from-to)1195-1202
    Number of pages8
    JournalAIDS
    Volume13
    Issue number10
    Publication statusPublished - 9 Jul 1999

    Fingerprint

    Opportunistic Infections
    Growth Hormone
    HIV
    Placebos
    Body Composition
    HIV Wasting Syndrome
    Proteins
    compound A 12
    Human Growth Hormone
    Therapeutics
    Leucine
    Counseling
    Fats
    Safety
    Infection

    Keywords

    • AIDS-Related Opportunistic Infections
    • Adult
    • Body Composition
    • Double-Blind Method
    • Growth Hormone
    • HIV Wasting Syndrome
    • Hand Strength
    • Human Growth Hormone
    • Humans
    • Male
    • Proteins
    • Quality of Life
    • Treatment Outcome
    • Growth hormone
    • HIV wasting
    • body composition
    • protein metabolism

    Cite this

    Paton, N. I., Newton, P. J., Sharpstone, D. R., Ross, H. M., Cotton, J., Calder, A. G., ... Griffin, G. E. (1999). Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. AIDS, 13(10), 1195-1202.

    Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. / Paton, N I; Newton, P J; Sharpstone, D R; Ross, H M; Cotton, J; Calder, Alexander Graham; Milne, Eric; Elia, M; Shah, S; Engrand, P; Macallan, D C; Gazzard, B G; Griffin, G E.

    In: AIDS, Vol. 13, No. 10, 09.07.1999, p. 1195-1202.

    Research output: Contribution to journalArticle

    Paton, NI, Newton, PJ, Sharpstone, DR, Ross, HM, Cotton, J, Calder, AG, Milne, E, Elia, M, Shah, S, Engrand, P, Macallan, DC, Gazzard, BG & Griffin, GE 1999, 'Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients', AIDS, vol. 13, no. 10, pp. 1195-1202.
    Paton NI, Newton PJ, Sharpstone DR, Ross HM, Cotton J, Calder AG et al. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. AIDS. 1999 Jul 9;13(10):1195-1202.
    Paton, N I ; Newton, P J ; Sharpstone, D R ; Ross, H M ; Cotton, J ; Calder, Alexander Graham ; Milne, Eric ; Elia, M ; Shah, S ; Engrand, P ; Macallan, D C ; Gazzard, B G ; Griffin, G E. / Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. In: AIDS. 1999 ; Vol. 13, No. 10. pp. 1195-1202.
    @article{2ec3d166aee345e387b99a62543d1d57,
    title = "Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients",
    abstract = "OBJECTIVES: A 12-week course of recombinant human growth hormone is an effective but expensive therapy for established HIV-related wasting. Wasting in HIV disease is often episodic, coinciding with bouts of acute opportunistic infection. We hypothesized that a short course of growth hormone, targeted at the time of opportunistic infection, might improve protein metabolism thereby reducing lean tissue loss. METHODS: HIV-infected men with acute opportunistic infections, who received standard antimicrobial treatment for their infection as well as intensive nutritional counselling and oral energy supplements, were randomized to receive growth hormone or placebo for 14 days. Principal assessments were protein metabolism (measured by 13C-leucine infusion), body composition (measured by DEXA) and safety. RESULTS: There were no significant changes in outcome parameters in the placebo group (n = 11). In the growth hormone group (n = 9), protein catabolic rate decreased by 60{\%} in the fasted state (P = 0.02 versus placebo), lean body mass increased by 2.2 kg (P = 0.03 versus baseline) and fat mass decreased by 0.7 kg (P = 0.002 versus baseline). There was no increase in adverse or serious adverse events in the growth hormone as compared with the placebo group. CONCLUSIONS: A two-week course of growth hormone at the time of acute opportunistic infection in HIV-infected patients improves protein metabolism and body composition during therapy and appears to be safe. This may represent a rational and economical approach to the use of growth hormone therapy.",
    keywords = "AIDS-Related Opportunistic Infections, Adult, Body Composition, Double-Blind Method, Growth Hormone, HIV Wasting Syndrome, Hand Strength, Human Growth Hormone, Humans, Male, Proteins, Quality of Life, Treatment Outcome, Growth hormone, HIV wasting, body composition, protein metabolism",
    author = "Paton, {N I} and Newton, {P J} and Sharpstone, {D R} and Ross, {H M} and J Cotton and Calder, {Alexander Graham} and Eric Milne and M Elia and S Shah and P Engrand and Macallan, {D C} and Gazzard, {B G} and Griffin, {G E}",
    year = "1999",
    month = "7",
    day = "9",
    language = "English",
    volume = "13",
    pages = "1195--1202",
    journal = "AIDS",
    issn = "0269-9370",
    publisher = "Lippincott Williams and Wilkins",
    number = "10",

    }

    TY - JOUR

    T1 - Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients

    AU - Paton, N I

    AU - Newton, P J

    AU - Sharpstone, D R

    AU - Ross, H M

    AU - Cotton, J

    AU - Calder, Alexander Graham

    AU - Milne, Eric

    AU - Elia, M

    AU - Shah, S

    AU - Engrand, P

    AU - Macallan, D C

    AU - Gazzard, B G

    AU - Griffin, G E

    PY - 1999/7/9

    Y1 - 1999/7/9

    N2 - OBJECTIVES: A 12-week course of recombinant human growth hormone is an effective but expensive therapy for established HIV-related wasting. Wasting in HIV disease is often episodic, coinciding with bouts of acute opportunistic infection. We hypothesized that a short course of growth hormone, targeted at the time of opportunistic infection, might improve protein metabolism thereby reducing lean tissue loss. METHODS: HIV-infected men with acute opportunistic infections, who received standard antimicrobial treatment for their infection as well as intensive nutritional counselling and oral energy supplements, were randomized to receive growth hormone or placebo for 14 days. Principal assessments were protein metabolism (measured by 13C-leucine infusion), body composition (measured by DEXA) and safety. RESULTS: There were no significant changes in outcome parameters in the placebo group (n = 11). In the growth hormone group (n = 9), protein catabolic rate decreased by 60% in the fasted state (P = 0.02 versus placebo), lean body mass increased by 2.2 kg (P = 0.03 versus baseline) and fat mass decreased by 0.7 kg (P = 0.002 versus baseline). There was no increase in adverse or serious adverse events in the growth hormone as compared with the placebo group. CONCLUSIONS: A two-week course of growth hormone at the time of acute opportunistic infection in HIV-infected patients improves protein metabolism and body composition during therapy and appears to be safe. This may represent a rational and economical approach to the use of growth hormone therapy.

    AB - OBJECTIVES: A 12-week course of recombinant human growth hormone is an effective but expensive therapy for established HIV-related wasting. Wasting in HIV disease is often episodic, coinciding with bouts of acute opportunistic infection. We hypothesized that a short course of growth hormone, targeted at the time of opportunistic infection, might improve protein metabolism thereby reducing lean tissue loss. METHODS: HIV-infected men with acute opportunistic infections, who received standard antimicrobial treatment for their infection as well as intensive nutritional counselling and oral energy supplements, were randomized to receive growth hormone or placebo for 14 days. Principal assessments were protein metabolism (measured by 13C-leucine infusion), body composition (measured by DEXA) and safety. RESULTS: There were no significant changes in outcome parameters in the placebo group (n = 11). In the growth hormone group (n = 9), protein catabolic rate decreased by 60% in the fasted state (P = 0.02 versus placebo), lean body mass increased by 2.2 kg (P = 0.03 versus baseline) and fat mass decreased by 0.7 kg (P = 0.002 versus baseline). There was no increase in adverse or serious adverse events in the growth hormone as compared with the placebo group. CONCLUSIONS: A two-week course of growth hormone at the time of acute opportunistic infection in HIV-infected patients improves protein metabolism and body composition during therapy and appears to be safe. This may represent a rational and economical approach to the use of growth hormone therapy.

    KW - AIDS-Related Opportunistic Infections

    KW - Adult

    KW - Body Composition

    KW - Double-Blind Method

    KW - Growth Hormone

    KW - HIV Wasting Syndrome

    KW - Hand Strength

    KW - Human Growth Hormone

    KW - Humans

    KW - Male

    KW - Proteins

    KW - Quality of Life

    KW - Treatment Outcome

    KW - Growth hormone

    KW - HIV wasting

    KW - body composition

    KW - protein metabolism

    M3 - Article

    VL - 13

    SP - 1195

    EP - 1202

    JO - AIDS

    JF - AIDS

    SN - 0269-9370

    IS - 10

    ER -